NERVGEN PHARMA CORP.
NGENNext catalyst
NVG-291
Spinal Cord Injuries
Get an email about NGEN's next catalysts
Track NERVGEN PHARMA (NGEN) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 1 past
NVG-291 Phase 3 Est. Readout (RESTORE)
Estimated primary completion for NVG-291 trial (NCT07799532) in Chronic Spinal Cord Injury. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
NVG-291 | Phase 3 | Spinal Cord Injuries | - | - |
Frequently asked questions
What is in NERVGEN PHARMA CORP.'s drug pipeline?β
CatalystAlert tracks 1 drug candidate in NERVGEN PHARMA CORP.'s (NGEN) pipeline across Phase 3. Its lead program is NVG-291 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is NERVGEN PHARMA CORP.'s next FDA catalyst?β
NERVGEN PHARMA CORP.'s (NGEN) next tracked catalyst is a Phase 3 readout expected July 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track NGEN biotech catalysts?β
Add NGEN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow NERVGEN PHARMA CORP.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
